SKU: Q007  / 
    CAS Number: 512-64-1

    Quinomycin A

    $52,640.64 - $183,419.73
    Quinomycin A

    Quinomycin A is a cyclic depsipeptide metabolite. Quinomycin A has broad activity against bacteria, fungi and viruses, and has found application as an antitumor agent. Quinomycin A acts by bifunctional intercalation of nucleic acids. Quinomycin A is an extremely potent inhibitor of hypoxia-inducible factor-1 (HIF-1). This transcription factor plays an essential role in tumor progression and metastasis.

    Quinomycin A is soluble in DMF and DMSO and has limited solubility in ethanol and methanol. 

    Molecular Formula C51H64N12O12S2
    Cancer Applications Cancer stem cells (CSCs) likely account for enhanced therapeutic resistance following cancer treatment.  Dysregulated Notch signaling, which affects CSCs, plays an important role in the progression of pancreatic cancer.  Quinomycin can inhbiit CSCs and the Notch signaling pathway, and it was able to inhibit proliferation/colony formation in pancreatic cell lines but not in normal pancreatic epithelial cells. 
    References

    Cuesta-Seijo JA et al (2006)  Serendipitous SAD phasing of an echinomycin-(ACGTACGT)2 bisintercalation complex. Acta Crystallogr. D Biol. Crystallogr. 62:417

    Kong D et al (2005)  Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.  Cancer Res. 65:9047

    Park JY et al (2004)  Echinomycin and a novel analogue induce apoptosis of HT-29 cells via the activation of MAP kinases pathway. Pharmacol Res. 50:201

    Ponnurangam S et al (2016)  Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells. Oncotarget. 7(3):3217-3232  PMID 26673007